INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, ...

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of ...

MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB” or the "Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

Marketed as Tecartus (autologous anti-CD19-transduced CD3+) in Europe, the drug was approved in the EU in December for adults with relapsed or refractory mantle cell lymphoma after two or more ...

This subcutaneous CD19/CD3-directed bispecific-TCE (BiTE) demonstrated deep B-cell depletion and a favourable safety profile with weekly injections in Phase 1 trials for non-Hodgkin’s lymphoma ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

We’ve long known follicular lymphoma (FL) as a slow-growing, incurable disease that tends to relapse. For many patients, that has meant cycling through treatments over decades, each remission a ...

In the treatment of non-Hodgkin lymphoma with CD19 chimeric antigen receptor (CAR) T-cell therapy, baseline kidney function did not appear to be associated with an increased risk of developing ...

Methods and Results: We hypothesized that simultaneous targeting of NKG2DL (using the NKG2D extracellular domain) and CD19 can prevent CD19 antigen escape and improve long-term remission rates in ...

Correspondence to Dr Falk Hiepe, Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Charitéplatz 1, Berlin 10117, Germany; falk.hiepe{at}charite.de Objectives To ...